comparemela.com

Latest Breaking News On - Valeria fisher sophia hergenhan - Page 1 : comparemela.com

Vivoryon Therapeutics N V : Vivoryon Therapeutics N V to Participate in Upcoming Investor Conferences

DGAP-News: Vivoryon Therapeutics N.V. / Key word: Conference Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. to Participate in Upcoming Investor Conferences 04.01.2022 /. | January 4, 2022

Valeria fisher sophia hergenhanUlrich dauerHc wainwright bioconnectManuela baderMichael schaefferJp morgan health care conferenceTrophic communicationsUpcoming investorEuronext amsterdamInvestor relationsVivoryon therapeuticsnv stock exchangePress releaseOnferences vvy nl00150002q7

DGAP-News: Vivoryon Therapeutics N V : Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer s Disease

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer's

Noord hollandValeria fisher sophia hergenhanUlrich dauerHalle saaleManuela baderDrug administrationNews serviceTrophic communicationsDistribution servicesVivoryon therapeutics receivesTrack designationEarly alzheimerGermany decemberEuronext amsterdamFast trackEuropean phase

DGAP-News: Vivoryon Therapeutics N V : Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer s Disease

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer s Disease (news with additional features) 22.12.2021 / 07:00 The issuer is solely responsible for the con.

Noord hollandValeria fisher sophia hergenhanUlrich dauerHalle saaleManuela baderDrug administrationNews serviceTrophic communicationsDistribution servicesVivoryon therapeutics receivesTrack designationEarly alzheimerGermany decemberEuronext amsterdamFast trackEuropean phase

Vivoryon Therapeutics N V : Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutam

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): Miscellaneous22.12.2021 / 07:00 The issuer is solely responsible for the content of this announcement.Vivoryon Therapeutics Receives FDA Fast Track Designation for Varoglutamstat in Early Alzheimer's Disease Halle (Saale) / Munich, Germany December 22, 2021 -.

Valeria fisher sophia hergenhanUlrich dauerManuela baderDrug administrationTrophic communicationsDistribution servicesTrack designationEarly alzheimerGermany decemberEuronext amsterdamFast trackEuropean phaseAccelerated approvalPriority reviewVivoryon fast trackCorporate news

DGAP-News: Vivoryon Therapeutics N V : Vivoryon Therapeutics N V Reports Q3 2021 Financial Results and Highlights Operational Progress

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): 9 Month figures Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports Q3 2021 Financial Results and Highlights Operational Progress (news with additional features) 04.11.2021 / 07:00 The issuer is solely responsible for the content of.

Noord hollandValeria fisher sophia hergenhanUlrich dauerHalle saaleManuela baderHoward feldmanNational institutes of healthTrophic communicationsInternational journal of molecular sciences hoffmannDistribution servicesAlzheimer disease cooperative studyJournal alzheimer research therapy vijverbergNews serviceNational institute on agingHighlights operational progressHighlights operational

vimarsana © 2020. All Rights Reserved.